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Abstract: The tumor microenvironment (TME) is shaped by cancer and noncancerous cells,
the extracellular matrix, soluble factors, and blood vessels. Interactions between the cells, matrix,
soluble factors, and blood vessels generate this complex heterogeneous microenvironment. The TME
may be metabolically beneficial or unbeneficial for tumor growth, it may favor or not favor
a productive immune response against tumor cells, or it may even favor conditions suited to hijacking
the immune system for benefitting tumor growth. Soluble factors relevant for TME include oxygen,
reactive oxygen species (ROS), ATP, Ca2+, H+, growth factors, or cytokines. Ca2+ plays a prominent
role in the TME because its concentration is directly linked to cancer cell proliferation, apoptosis,
or migration but also to immune cell function. Stromal-interaction molecules (STIM)-activated Orai
channels are major Ca2+ entry channels in cancer cells and immune cells, they are upregulated in
many tumors, and they are strongly regulated by ROS. Thus, STIM and Orai are interesting candidates
to regulate cancer cell fate in the TME. In this review, we summarize the current knowledge about
the function of ROS and STIM/Orai in cancer cells; discuss their interdependencies; and propose
new hypotheses how TME, ROS, and Orai channels influence each other.
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1. Introduction
The tumor microenvironment (TME) (Figure 1) has a significant influence on carcinogenesis
(tumor development). The TME is generated by cancer and noncancerous cells, including immune
cells, cell–cell interactions, the extracellular matrix, and soluble factors. Soluble factors include
oxygen; nutrients; reactive oxygen species (ROS); reactive nitrogen species (RNS); ATP; Ca2+, H+,
and other ions; growth factors; chemokines; cytokines; or waste products [1–4]. The intracellular
Ca2+ concentration ((Ca2+)int) is a key regulator of (cancer) cell proliferation and apoptosis and, thus,
should play an important role in tumor growth and development. Ca2+ influx across the plasma
membrane is a major mechanism to shaping (Ca2+)int in all cells, including cancer and immune
cells [5–9]. Stromal-interaction molecules (STIM)-activated Orai channels represent the main Ca2+
channel type in most electrically unexcitable cells including immune cells [6,7,9] but also many cancer
cells [5,10,11]. Their expression in cancer cells is found to be correlated with metastatic progression,
a poor prognosis, and a shorter survival. Since malignant cells exhibit a strong dependence on Ca2+
flux for proliferation, Orai channels could be considered a potential therapeutic target to inhibit
cancer growth.
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Figure 1. An overview of the tumor microenvironment (TME): The TME is composed by a diverse 
range of cell types, including tumor cells, immune cells, epithelial cells, and stromal cells. Areas of 
low nutrients and O2 result in necrotic regions. The TME controls tumor growth by diverse 
mechanisms that are further discussed in the text. 
ROS have recently been in the focus of TME research because, depending on their 
concentrations, ROS may be decisive for the life and death of cancer cells [12,13]. Since Orai1 and 
Orai2 but not Orai3 channels are strongly regulated by ROS [14–16], Orai channels are interesting 
targets to integrate Ca2+ influx and ROS signaling in the TME. In this review, we focus on the 
interactions of Orai channels and ROS in the TME and on their potential relevance for TME 
development. We propose a scenario where redox changes alter Orai function and Ca2+ influx in both 
malignant and nonmalignant cells, such as immune cells, resulting in changes in (Ca2+)int with a direct 
impact on tumor fate. 
2. The Tumor Microenvironment (TME) 
According to the World Health Organization (WHO), cancer is “the second leading cause of 
death globally and is estimated to account for 9.6 million deaths in 2018” (World Health 
Organization). The process of cancer development and progression is called carcinogenesis and is 
divided into 3 to 4 distinct steps called initiation, promotion, progression, and metastasis [17]. 
In solid tumors, the tumor mass is formed by a diverse milieu which is composed of malignant 
and nonmalignant cells such as endothelial cells, cancer-associated fibroblasts, immune cells, adipose 
cells, and neuroendocrine cells in addition to vascular and lymphatic networks and the extracellular 
matrix (ECM) [1]. This dynamic and complex multicellular environment is known as the tumor 
microenvironment (TME) (Figure 1). The TME has long been considered an important factor for 
tumor growth: The first publications are from the 19th century [18]! In the past few years, the TME 
and noncancerous cells have been recognized as major players for tumor growth [19,20] and, 
therefore, as potential targets for drug actions. However, due to its complexity, the TME and its 
cancer-type specific features still remain an obstacle for efficient cancer therapy [3]. Many of the 
molecular mechanisms of signaling pathways within the TME are not well-understood and the 
complex interactions between cellular and non-cellular TME components are not well-defined. A 
detailed understanding of the TME and its interactions would allow for better pharmacological 
treatment and a better tumor prognosis. 
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2. The Tumor Microenvironment (TME)
According to th World Health Organization (WHO), cancer is “the second leading cause of
death globally and is estimated to account for 9.6 million deaths in 2018” (World Health Organization).
The process of cancer development and progression is called carcinogenesis and is divided into 3 to 4
distinct steps called initiation, promotion, progression, and metastasis [17].
In solid tumors, the tumor mass is formed by a diverse milieu which is composed of malignant
and nonmalignant cells such as endothelial cells, cancer-associated fibroblasts, immune cells, adipose
cells, and neuroendocrine cells in addition to vascular and lymphatic networks and the extracellular
matrix (ECM) [1]. This dynamic and complex multicellular environment is known as the tumor
microenvironment (TME) (Figure 1). The TME has long been considered an important factor for tumor
growth: The first publications are from the 19th century [18]! In the past few years, the TME and
noncancerous cells have been recognized as major players for tumor growth [19,20] and, therefore,
as potential targets for drug actions. However, due to its complexity, the TME and its cancer-type
specific features still remain an obstacle for efficient cancer therapy [3]. Many of the molecular
mechanisms of signaling pathways within the TME are not well-understood and the complex
interactions between cellular and non-cellular TME components are not well-defined. A detailed
Cancers 2019, 11, 457 3 of 28
understanding of the TME and its interactions would allow for better pharmacological treatment and
a better tumor prognosis.
Depending on the cellular and non-cellular composition, the local milieu can be highly variable
between different tumors or even within the same tumor (Figure 1). The metabolism of different
cell types, cell–cell interactions, the architecture of TME formed by remodeling of ECM proteins
(which create a stiff fibrotic matrix), and the blood supply together create an environment composed
of oxygen; nutrients; reactive oxygen species (ROS); reactive nitrogen species (RNS); ATP; Ca2+, H+,
and other ions; growth factors; chemokines; cytokines; or waste products (Figure 1). This environment,
together with locally secreted molecules from different cells, leads to pH gradients, differences in
oxygen tension, and interstitial pressure across the tumor [2,4,21]. These parameters have an impact
on the metabolism of surrounding cells and consequently cellular function, where the environment is
constantly changing and adapting according to new challenges and interactions with the host.
It has been shown that the TME can promote cancer growth and metastasis as a result of
bidirectional interactions between cancer cells, noncancerous cells, and the surrounding environment.
In the worst scenario, the TME forms a niche favorable to tumor growth and less favorable to other
cells that could eliminate or limit tumor cell proliferation. In fact, it has been shown that most of
the nonmalignant cells within the TME often adopt a tumor-promoting phenotype after the local
milieu modifies their cellular functions [22]. Such alterations include changes in gene expression
and cellular activity. For example, hypoxia, which develops at the beginning of tumor growth and
induces cell necrosis (Figure 1), leads to the activation of hypoxia-responsive genes in malignant
and nonmalignant cells. It also promotes the recruitment and survival of immune cells that are
mainly glycolytic, such as macrophages, which produce large amounts of ROS [3]. This has drastic
consequences for the cells present in this niche, as they need to adapt to be able to survive in this highly
oxidative environment. Increased ROS also activates pathways in leukocytes to secrete more cytokines
that favor tumor growth, leads to new cellular mutations, and may, therefore, transform other cells
and induce apoptosis. Regions that undergo cycling hypoxia are also present in the TME. Cycling
here refers to situations of fluctuating oxygen levels, going from deep hypoxia to moderate hypoxia
states, similar to the reoxygenation of blood vessels in the human heart after ischemia, which bares the
risk of ischemia-reperfusion injury [23]. Cycling hypoxia can affect cells near blood vessels, which are
not efficiently perfused, contrary to hypoxic regions which are normally far from blood vessels [24].
Cells exposed to cycling hypoxia need to deal with and to adapt to two conditions: a lack of oxygen and
sudden reoxygenation, which leads to very high amounts of ROS. All these changes can create different
sub-microenvironments within the TME, each of them having distinct characteristics, populated by
different cells, and exposed to different molecules.
3. STIM/Orai Channels in Cancer
Like all cells, cancer cells of the TME express a whole range of different ion channels. Considering
the importance of Ca2+ for cell signaling including proliferation, migration, and apoptosis in
combination with the strong dependence of cancer growth on these mechanisms, Ca2+ channels
should play a very important role in the TME. Among Ca2+ channels, Orai channels have a prominent
role in many electrically unexcitable cells [6,7,9]. They represent the main Ca2+ channel in most
immune cells in which they were initially discovered [25], but they are also highly expressed in cancer
cells and correlate with metastatic progression, a poor prognosis, and a shorter survival [5–8,10,11].
Since malignant cell functions depend on Ca2+ flux, considerable interest has emerged in the
therapeutic potential of inhibiting Orai for many cancer types.
3.1. Short Introduction to STIM and Orai
Store-operated Ca2+ entry (SOCE) is the major Ca2+ entry pathway including cancer and immune
cells [5–8,10,11]. Its well-known activation mechanism is depicted in Figure 2. The two known SOCE
activators, STIM1 and STIM2, sense the ER Ca2+ store content and activate Orai channels in the
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plasma membrane. STIMs are known to form homomultimers (as depicted in Figure 2) but may also
form heteromultimers [26]. STIM1 is less sensitive to ER luminal Ca2+ compared to STIM2 [27] but
activates Orai channels significantly stronger [28]. There are three known isoforms of the tetraspanning
hexameric Orai channels, Orai1, Orai2, and Orai3 (Figure 2), with characteristic properties [29,30].
All of them are activated after the depletion of Ca2+ from the ER, possess a high selectivity for Ca2+,
are inwardly rectifying, and show a Ca2+-dependent inactivation (CDI) [30].
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Figure 2. Store-operated Ca2+ entry (SOCE) by stromal-interaction molecule (STIM)/Orai channels in 
cancer cells: Following the stimulation of G protein- or tyrosine kinase-coupled (G/T) receptors (R), 
phospholipase C (PLC) hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 
trisphosphate (IP3). The latter binds to its receptor, a Ca2+ release channel in the endoplasmic reticulum 
(ER) membrane and opens it, which induces the Ca2+ depletion of ER Ca2+ stores. A drop of (Ca2+)ER 
activates luminal Ca2+ sensor proteins, the STIMs. Activated STIMs oligomerize and move to the 
plasma membrane where they bind and open Orai channels, leading to a Ca2+ influx across the plasma 
membrane. Plasma membrane Ca2+ ATPases (PMCAs), Na+–Ca2+ exchangers (NCX), and sarco-
/endoplasmic reticulum Ca2+ ATPases (SERCAs) export Ca2+ from the cytosol. 
3.2. STIM/Orai in Tumor Initiation and Promotion 
Initiation is the first step in cancer development where normal cells undergo irreversible 
changes, transform, escape the immune surveillance, undergo continuous unregulated proliferation, 
and are able to form tumors at the end. The loss of growth control involves a whole range of critical 
mutations and is the sum of the accumulated abnormalities in a cell’s regulatory systems. Whether 
changes in (Ca2+)int are relevant for cancer initiation is currently not clear [5]. 
A mechanistic link between Ca2+ homeostasis and chromosome instability was recently 
proposed in hepatocytes with Hepatitis B viral (HBV) infection, as the driver of hepatocellular 
carcinoma [31]. The hepatocytes carry a gain-of-function mutation in the preS2 region of a large 
surface antigen (LBHS), one of two HBV-encoded oncoproteins, that is linked to the early onset of 
hepatocellular carcinoma. The preS2 mutation promotes ER-plasma membrane (PM) connections 
through ER stress and causes the permanent activation of SOCE in these cells, inducing chromosome 
instability, aneuploidy, and anchorage-independent growth [31]. However, more in vivo studies and 
direct evidence are necessary to prove or disprove a role of SOCE and, thus, Ca2+ as cancer initiators 
or drivers. 
3.3. STIM/Orai in Tumor Proliferation/Growth 
Orais and STIMs are expressed in the vast majority of tumors [5,10]. Their expression levels seem 
to correlate with metastatic progression, a poor prognosis, and a shorter survival in studies using 
patient specimens. Colorectal cancer patients with a positive expression of STIM1 [32] or/and with a 
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results for Orai1 were also shown for non-small cell lung cancer [34], esophageal squamous cell 
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3.2. STIM/Orai in Tumor Initiation and Promotion
Initiation is the first step in cancer development where normal cells undergo irreversible changes,
transform, escape the immune surveillance, undergo continuous unregulated proliferation, and are
able to form tumors at the end. The loss of growth control involves a whole range of critical mutations
and is the sum of the accumulated abnormalities in a cell’s regulatory systems. Whether changes in
(Ca2+)int are relevant for cancer initiation is currently not clear [5].
A mechanistic link between Ca2+ homeostasis and chromosome instability was recently proposed
in hepatocytes with Hepatitis B viral (HBV) infection, as the driver of hepatocellular carcinoma [31].
The hepatocytes carry a gain-of-function mutation in the preS2 region of a large surface antigen (LBHS),
one of two HBV-encoded oncoproteins, that is linked to the early onset of hepatocellular carcinoma.
The preS2 mutation promotes ER-plasma membrane (PM) connections through ER stress and causes
the permanent activation of SOCE in these cells, inducing chromosome instability, aneuploidy,
and anchorage-independent growth [31]. However, more in vivo studies and direct evidence are
necessary to prove or disprove a role of SOCE and, thus, Ca2+ as cancer initiators or drivers.
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3.3. STIM/Orai in Tumor Proliferation/Growth
Orais and STIMs are expressed in the vast majority of tumors [5,10]. Their expression levels seem
to correlate with metastatic progression, a poor prognosis, and a shorter survival in studies using
patient specimens. Colorectal cancer patients with a positive expression of STIM1 [32] or/and with
a high Orai1 expression had poorer prognoses and shorter overall survival rates [33]. Comparable
results for Orai1 were also shown for non-small cell lung cancer [34], esophageal squamous cell
carcinoma [35], and gastric cancer [36]. Additionally, Orai3 expression was increased in tumor
tissues of lung adenocarcinoma [37], prostate cancer [38], and breast cancer [39] and correlated with
overall survival and metastasis-free survival [37]. Interestingly, an analysis of a microarray from
McAndrew and colleagues revealed a significantly poorer prognosis [40] for breast cancer patients
with a STIM1-high and STIM2-low phenotype. Considering that not only the ratio between STIM1,
STIM2, Orai1, Orai2, and Orai3 but also the discovery of STIM2 splice variants [41,42] are highly
relevant for Ca2+ channel activity [43–47], the relative composition of STIMs and Orais needs to be
carefully addressed not only in tumors.
Cell proliferation is dependent on the cell cycle and transitions between different phases (G0/G1,
S phase, and G2/M phase) which are tightly controlled through Ca2+-dependent checkpoints (reviewed
in Reference [48]). SOCE alters cancer cell proliferation in vitro [49–51] and also in vivo [33,35,36,52–54].
However, how Ca2+ controls distinct checkpoints is not well-understood. Increases in the basal or
transient fluctuation of Ca2+ are involved, but also (Ca2+)ext needs to be considered. Cell cycle arrest in
the G0/G1 phase in U251 cells [53], in neck squamous cell carcinoma cell lines [54], and at the S and
G2/M phases in cervical cancer cells [52] by STIM1-silencing has been reported. A pro-proliferative
role of STIM1 in vivo using U251 human glioma xenograft model in mice revealed that knocking
down STIM1 in xenografts demonstrated a diminished growth [53]. In contrast, an elevated Orai1
and/or STIM1 expression can promote cell proliferation [36,54]. In non-small lung cancer cells,
nicotine promotes cell proliferation by upregulating Orai1 expression and therefore by enhancing
SOCE and increasing basal Ca2+ concentration [55]. In esophageal squamous cell carcinoma zinc
is able to inhibit Orai1-mediated SOCE, Ca2+ oscillations, and subsequent cell proliferation [56].
The pharmacological inhibition or knocking down of Orai channel could block human esophageal
squamous cell carcinoma proliferation in vitro and tumor growth in vivo [35]. Another study shows
that high Ca2+ diet in a mouse model of slowly evolving prostate cancer accelerated its progression
by promoting proliferation [57] indicating the importance of (Ca2+)ext. Growth factors as fibroblast
growth factor 4 (FGF4) may also have an impact on Orai1 expression, resulting in increased SOCE,
and may promote epithelial-mesenchymal transition and enhanced cell proliferation [58]. One of the
most important and interesting cascades in this context is the mTOR (mechanistic target of rapamycin)
pathway (reviewed in Reference [59]). As the catalytic subunit of two distinct protein complexes
(mTORC1 and C2), this serine/threonine protein kinase plays a central role for the cell perception of
the environment in the regulation of metabolism, cell cycle, and growth. It is, thus, essential for the
adaptability of cells to specific changes and needs as in the TME. A recent study showed an interesting
relationship between mTORC1 and STIM1 expression as a novel potential therapeutic approach for
patients with tuberous sclerosis complex (TSC) tumors [60].
Not only the main players of SOCE, STIM1 and Orai1, but also the slightly “neglected” STIM2 and
Orai3 are involved in proliferation and growth of tumor cells [61]. The overexpression of STIM2
inhibits cell proliferation and tumor growth in colorectal cancers in vivo [62] but promotes cell
migration in primary melanoma in vivo [63], implicating the contribution of STIM2 signaling at
different stages of tumor progression. Furthermore, the high Orai1 and STIM2 expression found in
melanoma biopsies at the rim of invading tumors are linking their possible role in tumor invasion
and/or metastasis in vivo [63]. In human carcinoma cells versus normal mucosa cells, STIM2 protein
was nearly depleted in contrast to an upregulation of STIM1 and all three Orai proteins [64].
The involvement of Orai3 in the machinery of tumorigenesis has been reported, including breast,
prostate, and lung cancer [38,65–67]. By using mice xenograft models, it was shown that Orai3 plays
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a crucial role in prostate cancer development in vivo [38]. The knockdown of Orai3 significantly
reduced SOCE and inhibited proliferation by arresting non-small cell lung cancer cell lines in the
G0/G1 phase [67]. Orai3 transcripts are differentially expressed in the different subtypes of breast
cancer and regulated by estrogen receptor alpha (ERα). The silencing of ERα causes a decreased
expression of Orai3 and cell proliferation in vitro [65]. The same study places Orai3 as an important
player in tumorigenesis in vivo, since the growth of breast tumors was significantly reduced by
Orai3 knockdown before the transfer to the recipient mice with severe combined immunodeficiencies
(SCID) [65]. Orai3 expression seems to be regulated positively and negatively by miRNA and to
act directly on Orai3 3′UTR [68]. Another interesting finding places Orai1–Orai3 channel complexes
in the center of attention in a variety of prostate cancer cells [38]. The study reports an oncogenic
switch in which cells, especially those exposed to tumor microenvironmental factors (here, arachidonic
acid), change from homologous Orai1 complexes to more heterogeneous Orai1–Orai3 complexes by
upregulating Orai3 expression. This switch could be an excellent adaptation, where a shift from
a pro-apoptotic to more pro-proliferative phenotype is beneficial for cell proliferation and growth [38].
3.4. STIM/Orai in Tumor Survival/Apoptosis
A well-controlled balance between cell proliferation and cell death is necessary to avoid excessive
proliferation leading to cancer development. In cancer, a scenario with too little apoptosis dominates,
causing the expansion of malignant cells that are resistant to apoptosis. Despite being part of the
problem, apoptosis is a popular target in cancer treatment. Therefore, a better understanding of the
complex underlying mechanism of apoptosis is the key to developing more specific targets to execute
the lethal hit against cancer cells. Ca2+ plays a pivotal role in the mechanistic induction of apoptosis.
During apoptosis, (Ca2+)int is dramatically increased, and as a consequence, mitochondria take up
large amounts of it and induce apoptosis. Interrupting the prolonged Ca2+ influx through SOCE by
knocking down Orai/Stim or blocking it with specific inhibitors can counteract cell apoptosis.
Human colon carcinoma cells show increased Orai and STIM1 expression, but STIM2 is
almost depleted [64]. In noncancerous cells, the knockdown of STIM2 decreases SOCE while it
promotes apoptosis resistance. This finding suggests that the loss of STIM2 contributes to apoptosis
resistance in tumor cells. In addition, the blockage of STIM1-mediated SOCE can significantly
enhance chemotherapy-induced apoptosis in lung and pancreatic cancer cells [69,70]. In a pancreatic
adenocarcinoma cell line, a siRNA-mediated knockdown of Orai1 and/or STIM1 increases apoptosis
induced by chemotherapy drugs 5-fluorouracil or gemcitabine [70]. In addition, Orai1 downregulation
has been shown to contribute to the formation of an apoptosis-resistant phenotype in prostate cancer
cells [71]. Furthermore, the presence of an increased Orai3 expression, leading to the assembly of
more Orai1/Orai3 channel complexes can increase the resistance to apoptosis, as has been suggested
in the context of pancreas carcinoma [38]. Similar results are found in breast cancer cells where the
downregulation of Orai3 arrests cell-cycle progression and induces apoptosis but not in normal breast
epithelial cells [39].
A recent study placed Bcl-2 as a SOCE regulator to modify ER stress-induced apoptosis [72].
The Bcl-2 family plays a major role in the regulation of apoptosis. Its pro- or anti-apoptotic members
act mainly at the mitochondria level. Bcl-2 is the first identified anti-apoptotic protein capable of
preventing apoptosis in a Ca2+-dependent manner [73]. A mutant of Bcl-2 used in the study increased
the expression of SOCE components and depleted Ca2+ in the ER lumen, causing a massive Ca2+ influx
leading to caspase activation and apoptosis [72]. Additionally, several anticancer drugs that are used
to induce cancer cell apoptosis function through the dysregulation of Ca2+ signaling, for example,
in colon cancer cells or triple-negative breast cancer [74,75].
3.5. STIM/Orai in Epithelial-to-Mesenchymal Transition (EMT)/Cancer Progression
Changes in cell phenotypes, defined as epithelial-to-mesenchymal transition (EMT), are important
for tumor metastasis [76,77]. This transition is associated with an improvement in migratory and
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invasive properties. The list of EMT inducers is long, including growth factors secreted by the tumor
environment, cytokines, hypoxia, and metabolic changes. Additionally, the indispensable change
in gene expression is activated by complex regulatory networks, involving transcriptional control,
transcriptional factors, miRNAs, alternative splicing, posttranslational regulation, protein stability,
and subcellular localization [78]. Several studies already reported that an altered SOCE is linked to
EMT in prostate cancer [79], colon cancer [32], and gastric cancer [36]. Transforming growth factor
β1 (TGF-β1) in MCF7 breast cancer cells enhanced SOCE. Silencing the transcription factor Oct4
or significant inhibition via TGF-β1 upregulated the expression of STIM1 and Orai1 and promoted
invasion and metastasis by inducing EMT [80]. TGF-β-induced EMT seems to be differently regulated
by the expression of STIM2 (regulating non-store-operated Ca2+ entry) and by the expression of
STIM1 (regulating store-dependent Ca2+ entry) [81]. Another study describes the Orai3 and STIM1
requirement for TGF-β-dependent Snai1 transcription, a transcription factor upregulated during
EMT [82]. A similar study in lung adenocarcinoma cell lines shows that FGF4 was also able to induce
EMT by elevating Ca2+ entry via the expression of Orai1 channels [58].
3.6. STIM/Orai in Tumor Metastasis/Angiogenesis
Cell motility is partly mediated by a (Ca2+)int gradient [83,84], and several components of
migration mechanisms, such as cytoskeleton remodeling, leading edge guidance, and matrix
degradation, are Ca2+ sensitive [85]. Over the last ten years, in vitro and in vivo evidence
has accumulated that SOCE components are involved in cell motility, invasion, and tumor
metastasis [86]. The inhibition of SOCE or their components inhibit metastasis of breast
cancer [57,87,88], melanoma [63,89], colorectal cancer [32], prostate cancer [51], and gastric cancer [36].
Consistently, the overexpression of STIM1 enhances cell migration in cervical cancer [52] and colorectal
cancer [49]. Cell motility and, thus, metastasis are regulated by dynamic interactions between
cytoskeleton, myosin II and focal adhesions [90], which assemble and disassemble to mediate
cell migration [91]. STIM1-dependent signaling regulates focal adhesion turnover [52,87] required
for leading edge protrusion and trailing tail retraction and regulates actomyosin contractility [92].
Furthermore, silencing STIM1 significantly alters podosome dynamics, reduces cell invasiveness [93],
and regulates the dephosphorylation of focal adhesion kinase (FAK) by modulating focal adhesion
turnover [94,95] and the recruitment and association of active pTyr397-FAK and talin at focal
adhesions [92]. Similar results were found in breast cancer cells in a murine tumor metastasis
model [87], in colorectal cancer following a destabilization of STIM1 [96], and in glioma cell lines [95].
One important pathway to modulate cell migration, invasiveness, and metastasis is the
PI3K/Akt/mTOR signaling pathway. Akt plays a central role by phosphorylating many proteins
involved in the stabilization of actin cytoskeleton and by promoting migration via remodeling. SOCE is
positively regulated by the PI3K/Akt pathway, and this effect might be suppressed by targeting
receptor tyrosine kinases (RTK) [97]. The RTK protein family includes epidermal growth factor
receptors (EGFRs), FGF receptors, and vascular endothelial growth factor receptors (VEGFRs) [98]
which are heavily involved in cell migration [98] and angiogenesis. Upregulated VEGF production
by a high STIM1 expression in human cervical cancer cells regulates the focal-adhesion dynamics
of migratory cells [52]. Accordingly, the inactivation of PI3K/Akt signaling pathway by STIM1
knockdown reduced the migration and invasion of prostate cancer cells [51]. Furthermore, a lipid raft
SK3/TRPC1/Orai1 complex promotes cell migration in metastatic colorectal cancer. The formation
of this complex is favored by the phosphorylation of STIM by epidermal growth factor (EGF) and
the activation of Akt [99]. A SK3-Orai1 complex also plays a critical role in cell migration and bone
metastasis [88,99].
The proliferation and motility of cells are critical steps in angiogenesis. Due to continuous and
fast growth, tumors rely on the formation of new blood vessels to ensure an adequate supply of
oxygen and nutrients [100]. Low oxygen tension (hypoxia) promotes metastasis and is considered
as the key driver in angiogenesis [101,102]. Hypoxia is sensed by the tissue and triggers the
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cellular production of hypoxia-inducible factor 1 (HIF-1), a transcription factor that activates many
downstream pathways [103] including the expression of VEGF, TGF-β, and platelet-derived growth
factor (PDGF-β) [104]. Hypoxia is a common feature of the TME of most solid tumors, and hypoxic
cancer cells secret VEGFs to initiate tumor angiogenesis [100,105]. Interestingly, VEGF and FGF (and
others) increase (Ca2+)int. However, molecular mechanisms underlying SOCE-mediated angiogenesis
remain poorly understood.
In colon cancer [106] and in triple-negative breast cancer [107], hypoxia leads to the upregulation
of Orai1 by the Notch1 pathway. These data are in line with the findings that Notch1 signaling
pathways activate NFκB [108] and that NFκB regulates the expression of Orai1 and STIM1 [109].
Orai1 upregulation potentiates SOCE and activates the nuclear factor of activated T cells, NFAT4,
contributing to hypoxia-induced invasion and angiogenesis [106,107]. Hypoxia leads to the
accumulation of hypoxia-inducible factor 1-alpha (HIF-1α), a subunit of the transcription factor HIF,
which responds to alterations of available oxygen [110]. The hypoxia-induced accumulation of HIF-1α
was found to correlate with the overexpression of STIM1 in human and murine hepatocarcinoma
cells (HCCs) [111]. The increase in STIM1 expression is a consequence of a direct HIF-1α binding to
the promoter of STIM1 and leads to an increase in SOCE in HCCs promoting tumor growth [111].
During hypoxia, HIF-1α is stabilized and induces many genes like VEGF for a better adaptation
to this condition [112]. Since the production of ROS is augmented under hypoxic conditions [113]
and ROS inhibits the SOCE mediated by STIM1 and Orai1 or Orai2 [14–16], the overexpression of
STIM1 might be a countermeasure of the HCCs to provide the necessary Ca2+ signals for vital cell
functions. Furthermore, the expression of STIM2 was also reported [114] under hypoxic conditions.
In rat pulmonary arterial smooth muscle cells, hypoxia-related STIM2 overexpression is accompanied
by an increased SOCE and proliferation [114]. Apart from the hypoxia-induced induction of Orai1 and
STIMs, it was recently also reported that Orai3 expression was induced by HIF1α in MDA-MB-468 ERα
negative cells [115]. Unlike in ERα positive MCF-7 breast cancer cells [65,66] where Orai3 silencing
reduces SOCE, the upregulation of Orai3 did not contribute to SOCE in ERα negative cells [115].
However, since the Orai3 expression in breast cancer is highly dependent on the ERα expression itself,
one might speculate that the Orai1 complexes contribute significantly to Ca2+ signals in ERα negative
cells. These results place the channels and sensors as new targets in regulating hypoxia.
4. ROS Production and Elimination
As mentioned before, reactive oxygen species (ROS) are one of the key factors to influence the
TME, and they also modulate Orai channels (see below). In the following section, we summarize the
most common pathways and mechanisms in ROS metabolism with specific regard to the TME inspired
by two reviews [116,117].
ROS comprise a group of molecules that are generated via the partial reduction of O2 and establish
high chemical reactivity [116–118]. The one-electron reduction of oxygen leads first to the formation of
superoxide anion radical (•O2¯), which in turn is dismutated and further reduced to hydrogen peroxide
(H2O2) which is finally either fully reduced to water or partially reduced and split to hydroxyl radical
(OH•) and hydroxyl anion (OH¯) [119]. ROS is mainly produced by mitochondria, NADPH oxidases
(NOX), and other enzymes like xanthine oxidase and cytochrome P450 [116,117,120,121] (Figure 3).
Very high ROS levels can be produced in mitochondria when •O2¯ molecules are released during
ATP generation in the electron transport chain (ETC) [116,122]. Several endogenous and exogenous
factors influence mitochondrial ROS production, including mitochondrial membrane potential [123],
hypoxia, and nutrient metabolites but also cancer- and immune-related factors like TNF-α and Toll-like
receptors [117,124–127].
NOX complexes also produce very high levels of ROS (Figure 3). The production of ROS via the
NOX family occurs during the catalysis of electron transfer from NADPH to O2 and thereby produces
•O2¯ [117]. NOX-dependent ROS production requires the functional assembly of the NOX complex,
which can be mediated by different signaling molecules such as growth factors and, again, TNF-α and
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Toll-like receptors [117,128,129]. Similar to the mitochondrial ROS production, the release of •O2¯ is
dependent on the location of the NOX molecules. NOX comprises NOX1-5 and Duox1/2 [116] which
are present in the plasma membrane and intracellular membranes of the nucleus, mitochondria and
the endoplasmatic reticulum (ER) [117]. The specific isoforms at particular sites can lead to ROS release
either to the intracellular or extracellular spaces [117,121].Cancers 2019, 11, x 9 of 27 
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The quantification of ROS levels is a challenging task. Table 1 summarizes the most commonly
used approaches.
For more comprehensive overviews over certain technologies, we acknowledge the following
reviews which are also relevant for the conceptual design of Table 1: references [132–150].
Table 1. A summary of the most commonly used tools and probes to measure various ROS.
Technique or Method Tools and Examples Specificity (Potential) Applications
Fluorescence-
based assays
Dihydroethidium (DHE) •O2¯, if used with HPLC
in vitro, extra- and
intracellular,
cell suspensions




Amplex Red, Amplex UltraRed H2O2
Hydroxyphenyl Fluorescein (HPF) not specific









roGFP2 coupled to glutaredoxins EGSH




















others in vitro, cell suspensions
Electrochemical assays
Electrodes of various types and
sizes (macro-, mini-, micro-
ultramicro- and nanoelectrodes),
arrays, chips; additional redox
mediators
•O2¯, H2O2 and other
ROS





















in vivo EPR with different
functional spin traps and probes Various ROS
5. Impact of Reactive Oxygen Species (ROS) in the Tumor Microenvironment (TME)
ROS likely plays a dual role in cancer, both as initiating factors as well as downstream signaling
molecules as a result of malignant transformations. In the literature, numerous reviews are available
that deal with cancer and ROS, but it is often hard to distinguish between cancer development and
progression and between “good” and “bad” ROS, although these differences play important roles in
the whole topic [116].
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5.1. How Can ROS Support Carcinogenesis?
The first step of carcinogenesis is called initiation and refers to the alteration, change, or mutation
of genes that develop either spontaneously or due to an exogenous source [17]. ROS can induce
detrimental DNA damage via base modifications; inter-strand, intra-strand and DNA-protein
crosslinks; and the induction of double strand breaks [151] (Figure 4). The promotion of cancer
(cells) is considered a clonal expansion and accumulation of the pre-neoplastic cells that result from the
initiation process, while progression already refers to a malignant conversion of the cells into invasive
carcinoma [17,152]. Once tumors are initiated, there are several ways that ROS can drive promotion
and expansion. These can be roughly divided into 3 subgroups: the impairment of transcription
factors, signaling pathways, and epigenetics (Figure 4). We discuss the mechanisms most frequently
involved in the majority of cancer subtypes but cannot acknowledge every mechanism in-depth.
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The invasion of newly synthesized blood vessels to the network of tumor cells (angiogenesis)
is an important event in carcinogenesis which is responsible not only for the supply with nutrients,
immune cells, and oxygen but also for the disposal of waste products as well as tumor spreading
(metastasis) [153] (Figure 4). One of the most prominent pro-angiogenic factors is the vascular
endothelial growth factor (VEGF), which has been shown to be a key regulator in cancer angiogenesis
upon stimulation via several pathways, factors, and conditions [154]. One of the transcription factors
that leads to increased VEGF expression is HIF-1α [155]. Elevated ROS levels can suppress HIF-1α
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degradation, finally leading to an increased VEGF expression and subsequent angiogenesis in distinct
cancer types such as prostate and ovarian cancer and fibrosarcoma [116,156]. Another important
transcription factor in cancer is the nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB) [157]. Besides its well-known role in immune and inflammatory responses, cell proliferation,
and apoptosis [158], NF-κB can also promote tumor proliferation [116,117]. Interestingly, mitochondrial
ROS have been shown to activate NF-κB with the subsequent upregulation of the EGF receptor in
pancreatic cancer, inducing the formation of pre-neoplastic lesions [117].
Another ROS-sensitive transcription factor involved in cell transformation, proliferation,
and apoptosis is activator protein 1 (AP-1) [116,159]. In human colon cancer cells, the upregulation
of AP-1 due to H2O2 has been documented, leading to increased MMP7 levels that are involved in
tumor metastasis [160]. Furthermore, activated AP-1 enhances the expression of genes involved in
growth stimulation like cyclin D1 but suppresses genes involved in the growth inhibition of cell cycle
inhibitor p21, finally leading to an increased cell proliferation [116,161,162]. The tumor suppressor
gene p53 is a key regulator of anti-proliferative cellular responses and is mutated in many tumor cells,
resulting in a deleterious loss of function [163]. The ROS-dependent impairment of p53 expression
and its activation/inactivation are controversially discussed in the literature. It is evident that ROS can
directly inactivate p53 via the oxidation of cysteine residues in its DNA-binding domain [164], but the
downstream effects of this inactivation remain ambivalent. In general, the inactivation of p53 will
most likely leads to the loss of anti-proliferative effects, which are part of its tumor suppressor gene
function. On the other hand, elevated ROS levels can promote apoptosis, senescence, and DNA-repair
in a p53-dependent manner, finally leading to a reduced malignant transformation [116,165–168].
Of note, an impaired p53 expression can, in turn, have effects on ROS production itself, and functional
p53 can enhance the expression of antioxidants like GPX, catalase, and SOD2 [116]. This downstream
effect can be lost upon the mutation and absence of p53, finally leading to ROS accumulation and
a pro-tumorigenic phenotype [116,169]. Again contradictorily, p53 has been shown to maintain
mitochondrial health and to subsequently limit ROS generation and tumor development [116,170].
In summary, ROS-dependent p53 impairment and downstream effects are variable and seem to react
in feedback loop systems that can be both pro- and anti-tumorigenic.
ROS can further influence other signaling pathways that are important for cancer progression
such as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) protein kinase B (Akt) pathway
(PI3K/Akt) which plays an important role in cell metabolism, growth, proliferation, and survival [171].
Enhanced ROS levels have also been shown to inactivate negative regulators of this pathway (e.g.,
PTEN: phosphatase and tensin homolog and PTP1B: protein tyrosine phosphatase 1B) via cysteine
oxidation [116,117,172,173].
Another possibility of how ROS can affect tumor development and progression is through
epigenetic regulation. Epigenetic alterations in the TME are usually linked to DNA methylation
or acetylation in the promoter regions of genes that are crucial for cancer cell proliferation or
migration. In this regard, ROS can, for example, increase histone H3 acetylation of the promoter
region of the Snai2 gene, which leads to an increased slug transcription factor expression and the
subsequent enhancement of cell proliferation and migration [116,174]. Another study demonstrated
a H2O2-dependent downregulation of E-cadherin in hepatocellular carcinoma cells that was described
as a result of a hypermethylation in the promoter region upon the recruitment and ROS-dependent
upregulation of histone deacetylase 1 (HDAC1) and DNA methyltransferase 1 (DNMT1). In turn,
the loss of E-cadherin has been associated with epithelial-mesenchymal transition (EMT) that is favored
by Slug and Snail expression, resulting in metastatic cancer [116,175,176]. Furthermore, DNA oxidation
itself may lead to both hypermethylation and hypomethylation and subsequently inactivate tumor
suppressor genes or activate oncogenes, respectively [116,177–179].
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5.2. Sources of ROS in The Tumor Microenvironment
The importance of ROS for carcinogenesis immediately leads to the question of if there are ROS
sources in the TME (Figure 4). Already 30 years ago, it was shown that cancer cells can induce
pathologically increased ROS release [180]. However, analyzing ROS in the TME remains to be difficult,
despite the fact that more and more techniques to measure different ROS are being developed (Table 1).
A big challenge is that the unique TME is disrupted during preparation, leading to errors in analyses,
in particular with regard to tumor cell metabolism. Furthermore, finding proper controls for in vitro
studies is likewise challenging, as fast proliferating tumor cells can establish different ROS levels
already due to their diverse metabolic state and not necessarily due to malignant transformation [181].
Nevertheless, several reliable studies have been performed to analyze ROS formation in the TME as
reviewed in Reference [182]. The activation of oncogenes, the loss of tumor suppressor genes as well
as mitochondrial DNA mutations and hypoxia may lead to an enhancement of ROS levels in tumor
cells that further support carcinogenesis and malignancy [182]. Other publications further describe the
same mechanisms to be responsible for the NOX-dependent ROS release by tumor cells [183,184].
As mentioned earlier, the cellular environment of a tumor includes several noncancerous cell
types that are recruited upon tumor formation, such as cytokine-secreting T cells, macrophages,
neutrophils, and fibroblasts. Cytokines are very important drivers of ROS production in the TME and,
thus, further contribute to the mechanisms described in the section above. The exposure of tumor cells
to certain important cytokines like IFNγ, TNFα, and IL-1 was shown to increase ROS production by
tumor cells themselves in various cancer types [185], while the elevated ROS levels were attributed to
NOX elevation or mitochondria activity [186]. In addition, neutrophils and macrophages are known
to induce a rapid burst of superoxide formation during their killing activity, finally leading to the
enhanced production of hydrogen peroxide in the TME [185,187,188].
In summary, several studies revealed the existence of both tumor cell-related and noncancerous
sources of ROS that are available in a solid TME (Figure 4). Together, they build up a complex network,
partially influencing each other and thereby further amplifying ROS formation in the TME. However,
since each tumor has a distinct metabolic state, it is nearly impossible to make predictions on ROS
levels in a given TME. The prediction of ROS levels is further complicated by the fact that the tumor is
able to initiate an antioxidant defense upon a continuous exposure to high ROS concentrations.
5.3. What Are The Downstream Effects of Increased ROS in The Tumor Microenvironment?
Tumor-induced ROS release can further activate the signaling pathways discussed before, i.e.,
the modulation of transcription factors or epigenetic changes, which are involved in tumor initiation,
promotion, and progression. This might induce a positive feedback loop system beneficial for tumor
growth. In contrast, very high ROS levels may be toxic and may induce tumor cell death. To avoid this,
tumor cells activate a defense mechanism to escape cell death [117]. This is of particular importance in
metastatic tumors where cancer cells, detached from the extracellular matrix, are exposed to elevated
ROS levels, for example, in oxidizing environments like blood and viscera [117,189,190]. Antioxidant
pathways upregulated upon elevated ROS levels include nuclear factor erythroid 2 (Nrf2) upregulation,
the activation of the JNK/p38 pathway, and GSH and NADPH elevation.
It is of great importance to distinguish between “good” and “bad” ROS with regard to cancer
initiation and progression. In general, low ROS levels seem to be beneficial for tumor cells in
order to support the proliferative and invasive properties, but upon crossing a distinct threshold,
ROS can be toxic for tumor cells. Of note, some studies revealed that even low ROS levels
can induce anti-tumorigenic signaling in cancer, leading, for example, to cell cycle arrest and
senescence [116]. As an example, gene deletions in NOX4 have been documented in association
with the hepatocellular carcinoma of a high tumor grade, and NOX4 knockdown studies showed
an elevated proliferative capacity of liver tumor cells in vitro [191]. Several pathways are involved in
anti-tumorigenic ROS-related signaling, finally leading to downstream tumor cell apoptosis, autophagy,
or necroptosis [12].
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Hence, tumor cells might exhibit an adaptive behavior in order to deal with different stages of
ROS elevation. Apparently, tumor cells are able to distinguish between “good” and “bad” ROS and to
subsequently induce either prooxidant or antioxidant mechanisms. Although various studies already
proved antioxidant drugs to reduce cancer risk and progression [192], the application of this therapy
needs to be reviewed intensely prior to prescription in order to ensure a clear benefit of the treatment.
6. Impact of ROS on STIM/Orai Channels
6.1. Impact of ROS on Orai
In addition to the ROS-TME interactions outline above, which have received a lot of attention in
TME research, Orai channels are a relatively novel ROS target (Figure 5) but may play an important
role in integrating Ca2+ and ROS signaling in the TME. ROS modulates the function of Orai channels,
thereby modulating (Ca2+)int, which is of high relevance for tumor growth as discussed above. Bogeski
et al. showed that endogenous and overexpressed Orai1 channels are inhibited by H2O2 with an IC50
of 34µM [15]. The same was found for HEK cells overexpressing Orai2. In contrast, HEK cells solely
overexpressing Orai3 were not inhibited by H2O2 (Figure 5), indicating a ROS-sensitivity for Orai1
and Orai2 but not Orai3 [15].
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Major targets of ROS are reactive cysteine residues [193]. Orai1 and Orai2 both contain three
cysteine residues at amino acid positions 126, 143, and 195. Orai3 shares the first two cysteines but lacks
the cysteine at position 195, which is replaced by a glycine. The substitution of Cys-195 with a serine
in Orai1 conf rr d a partial resistance to H2O2, where s the insertion of a cysteine in Orai3 at the
r spective positi r ndered Orai3 H2O2 sensitive. Together, thes experiments indicate a prominent
role for Cys-195 in the redox-s nsitivity of Orai channels [15]. If Orai channels were already coupled
to and opened by a STIM protein, H2O2 did ot block the Orai cha nels, indicating that STIM-Orai
binding might mask Cys-195. This finding is particularly interesting for the STIM1 splice variant
STIM1L prim rily found in skeletal muscle cells [194]. I contrast to STIM1, STIM1L is coupled to
Orai1 at resting Ca2+ concentrations without prior store-depletion which would leave STIM1L-Orai1
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clusters insensitive to H2O2-mediated SOCE inhibition. The mode of action of the inhibition of Orai1
with H2O2 was attributed to an intramolecular interaction between the oxidized Cys-195, located in
transmembrane helix 3 with a serine at amino acid position 239, located in transmembrane helix 4,
causing the Orai channel to be in a closed conformation [14].
Considering the differences in redox-sensitivity between Orai1, Orai2, and Orai3 (Figure 5),
the ratio between the isoforms might be an interesting factor regulating Ca2+ signals under oxidative
stress conditions during pathophysiological situations like cancer. For primary human CD4+ T cells,
it was indeed shown that naïve cells increase their Orai3 to Orai1 ratio when differentiating into effector
cells, thereby reducing the channel’s redox-sensibility [15]. Since effector T cells are recruited to sites
of inflammation, like the TME, where ROS concentrations are increased, increasing the Orai3 to Orai1
ratio could represent an adaptation mechanism to maintain Ca2+ signals necessary for proliferation
and the production of cytokines. An Orai3 to Orai1 ratio change was also observed for monocytes
in response to a bacterial peptide and following the bronchoalveolar lavage of S. aureus infected
C57BL6/J mice [16]. Monocytes kill bacteria by rapid exocytosis of H2O2, which is produced by NOX2
in a SOCE-dependent manner [121,195]. Therefore, the switch to a less redox-sensitive composition of
hexameric Orai channels would be beneficial to counter the H2O2-mediated inhibition of SOCE and
a discontinuation of the killing pathway.
Not only immune cells but also cancer cells change the Orai3 to Orai1 ratio, thereby changing the
H2O2 dependence of Orai-based Ca2+ entry. However, the findings are more complicated. Whereas in
prostate cancer [196,197] and in basal breast cancer [115] the Orai3–Orai1 ratio was decreased, it was
increased in another prostate cancer study [38], in estrogen receptor-positive breast cancer [65,115,198]
and in non-basal breast cancer [115].
6.2. Impact of ROS on STIM
As discussed above, STIM1 and STIM2 differ in their sensitivity to luminal Ca2+ and their
efficiency to gate Orai channels. STIM1 contains two cysteines at amino acid positions 49 and 56
which were reported to be redox sensitive [199,200] (Figure 5). Prins et al. [200] stated that under
oxidizing conditions, a disulfide bond between Cys-49 and Cys-56 is formed. In contrast, Hawkins et
al. [199] were not able to detect this disulfide bond formation but showed that the luminal Cys-56 is not
oxidized by H2O2 but rather is S-glutathionylated under oxidizing conditions. This S-glutathionylation
near the protein’s Ca2+ binding domain (formed by an EF-hand motive) rendered STIM1 constitutively
active, thereby inducing SOCE independent of the Ca2+ filling state of the ER [199].
STIM2 is often described as the less abundant isoform because, in most tissues, STIM1 expression
prevails [61,201,202]. However, in the brain, STIM2 is reported to be dominant, and neurons of
STIM2-deficient mice are protected from apoptosis under oxidative stress, indicating a protective role
for STIM2 [203].
7. Interactions between TME, Orai, and ROS: Promoting or Inhibiting Tumor Progression
Tumorigenesis usually starts by mutations of driver genes [204–208] such as RAS, BRAF, or NF-1.
As tumors progress and the microenvironment develops, cells adapt to survive in this new environment,
characterized by different levels of oxygen, nutrients, ROS, ATP, Ca2+, H+, cytokines, or waste products.
It is obvious from the analysis of publications in this review including
references [5,10,52,79,86,209–211] that the expression of STIM-activated Orai channels is enhanced in
most cancer types. In agreement with the finding that the amplitude of Ca2+ influx correlates very well
with cell proliferation [212], it is expected that higher levels of STIM and/or Orai are beneficial for
cancer growth and metastasis. On the other hand, it should not be neglected that there are no hints up
to now that STIM and/or Orai channels work as cancer driver genes [5]. Nevertheless, the inhibition
of Orai channels should inhibit cancer growth, and thus, the blockage of Orai1 and 2 by H2O2 [14–16]
in the TME should inhibit cancer growth (see the Graphical abstract).
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In several cancers, the upregulation of Orai3 was reported [38,39,65–68]. An increase of Orai3
would increase the Orai3–Orai1 ratio, thereby generating H2O2-insensitive heteromultimeric Orai
channels (see the Graphical abstract). This, in turn, would allow enough Ca2+ entry in cancer cells to
promote proliferation, metastasis, invasion, and survival. Thus, higher ROS levels in this case would
be considered pro-tumorigenic, whereas in case the Orai3–Orai1 ratio is low and where mostly Orai1
homomultimers are formed, ROS levels would be considered anti-tumorigenic, resulting finally in
cancer cell death. The dual role of ROS for cancer growth has indeed been reported [12] and many
studies point to a beneficial role of a slightly oxidizing environment for tumor development, growth,
and metastasis.
The efficient cytotoxicity of immune cells against cancer cells is a key factor to eradicating
a tumor. Cytotoxic immune cells like cytotoxic T cells (CTL) or natural killer (NK) cells of the
immune system also rely on Ca2+ influx through STIM-activated Orai channels to fulfill their cytotoxic
functions [8,213–216]. Interestingly, a very low (Ca2+)int is optimal for the high cytotoxic efficiency of
CTL (and to a lesser amount also of NK cells) against cancer cells [216]. Thus, the inhibition of Ca2+
entry through Orai1 and Orai2 channels by slightly increased ROS in the TME may increase immune
cell cytotoxicity against a tumor. In addition, CD4+ T cells and monocytes were found to increase their
Orai3–Orai1 ratio upon activation [15,16]. This increase should protect immune cells against high ROS
concentrations (in particular H2O2) in the TME to enable them to fulfill their cytotoxic functions (see
the Graphical abstract). In general, the relative expression of STIMs and Orais and their respective
ratios is of high importance for cell functions [41–47], and this should also be the case in cancer cells.
Another theory for the susceptibility of different cancers to ROS is the threshold concept, proposed
two decades ago [217]. As a result of the elevated ROS concentrations in the TME, cancer cells are closer
to the cytotoxic threshold of ROS than noncancerous cells. Consequently, the further application of ROS
or the inhibition of antioxidants should lead to an imbalance in the interplay between ROS and the cell’s
antioxidant system, leading to cell death or an increased sensitivity to additional therapeutics [217].
To better understand and predict the interplay between ROS and (Ca2+)int, local parallel
measurements in the TME are necessary (see Table 1 for techniques to determine ROS levels) but not
easy to achieve. For instance, the concentration dependence of ROS (and mainly of H2O2) regarding
cancer cell proliferation or apoptosis and regarding CTL or NK cell cytotoxicity is unfortunately not
well-defined. If different between cancer and immune cells, this would open up interesting therapeutic
options. One pitfall to date is that, for many years, ROS measurements have relied on small chemical
probes or cellular markers, which lack specificity and are prone to artifacts. It is now clear that redox
changes are compartmentalized, pointing to the need of subcellular measurements and not only to rely
on whole cell or even population measurements. Local effects and a lack of good redox probes are
probably the reasons why there are many contradictions regarding the role of redox changes in cancer
initiation, progression, metastasis, and therapy. First used as anticancer drugs [218,219], antioxidants
have been shown to increase lung cancer progression [220] and melanoma metastasis in mice [221].
The same disappointing result occurred in the clinical trial SELECT, where dietary supplementation
with vitamin E significantly increased the risk of prostate cancer among healthy men [222]. This clearly
shows that, as expected, redox modulation in tumors is complex.
With the development of new methods using genetically encoded ratiometric redox sensors, it is
now possible to identify ROS sources and different redox species within tumors even at subcellular
levels [139,223,224]. The group of Dick et al. has expressed these sensors in a mouse model of non-small
lung cancer xenograft and has observed different regions of mitochondrial redox state within the
same tumor, varying from a very oxidized core, where a high percentage of necrotic cells was present
to very reduced areas and regions of highly heterogeneous redox levels [223]. If most tumors are
heterogeneous regarding their redox status as suggested by different O2, pH, and nutrient levels [3],
the function of antioxidants (or oxidants) in the TME is not easy to predict.
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8. Conclusions
STIM-activated Orai channels are likely important players in the TME to integrate Ca2+- and
ROS-dependent functions in both cancer and immune cells (see the Graphical abstract). Considering
the importance of local ROS and Ca2+ signaling in the TME, we need to better understand how/why
these different tumor regions develop and, mainly, what their impact is on local cellular cancer and
immune cell functions. Combining genetically encoded redox and Ca2+ sensors to analyze localized
ROS concentrations and (Ca2+)int in parallel in tumor tissues (if possible, in vivo) is important to test
the relevance of ROS-modulated Orai channels in the TME in a quantitative manner and to allow
reasonable predictions to target them pharmacologically.
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